Top Markets
Coin of the day
Onward Medical N.V. Onward Medical N.V.

Onward Medical N.V.

ONWD
Clasificación en acciones #20461
Onward Medical N.V. is a medical technology company dedicated to developing... Onward Medical N.V. is a medical technology company dedicated to developing innovative therapies for spinal cord injuries, operating both within the Netherlands and internationally. Among its primary offerings is ARCEX, a non-invasive, external platform. This system incorporates a wearable stimulator and a wireless programmer, designed to restore or significantly enhance hand and arm motor function for individuals living with spinal cord injuries. Complementing this is ARCIM, an implantable platform. ARCIM features an implantable pulse generator and a lead positioned near the spinal cord, empowering individuals with chronic paralysis to regain the ability to stand and walk, often with minimal or no external assistance. The company is also currently advancing the Up-LIFT Trial, a clinical study evaluating the safety and efficacy of ARCEX Therapy in restoring strength and mobility in the upper extremities of those affected by spinal cord injury. Established in 2014, Onward Medical N.V. maintains its headquarters in Eindhoven, Netherlands.
Precio por acción
$2.80
Capitalización bursátil
$130.65M
Cambio (1 día)
-0.42%
Cambio (1 año)
-52.80%
País
NL
Comercio Onward Medical N.V. (ONWD)

Categoría

Ganancias de Onward Medical N.V. (ONWD)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Onward Medical N.V., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Onward Medical N.V. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH